Cargando…
Targeting Non-Small Cell Lung Cancer Cells by Dual Inhibition of the Insulin Receptor and the Insulin-Like Growth Factor-1 Receptor
Phase III trials of the anti-insulin-like growth factor-1 receptor (IGF1R) antibody figitumumab in non-small cell lung cancer (NSCLC) patients have been discontinued owing to lack of survival benefit. We investigated whether inhibition of the highly homologous insulin receptor (IR) in addition to th...
Autores principales: | Vincent, Emma E., Elder, Douglas J. E., Curwen, Jon, Kilgour, Elaine, Hers, Ingeborg, Tavaré, Jeremy M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3691253/ https://www.ncbi.nlm.nih.gov/pubmed/23826179 http://dx.doi.org/10.1371/journal.pone.0066963 |
Ejemplares similares
-
Bariatric Surgery in Morbidly Obese Insulin Resistant Humans Normalises Insulin Signalling but Not Insulin-Stimulated Glucose Disposal
por: Chen, Mimi Z., et al.
Publicado: (2015) -
Loss of the insulin receptor in murine megakaryocytes/platelets causes thrombocytosis and alterations in IGF signalling
por: Moore, Samantha F., et al.
Publicado: (2015) -
Insulin Receptor Isoforms and Insulin Growth Factor-like Receptors: Implications in Cell Signaling, Carcinogenesis, and Chemoresistance
por: Galal, Mariam Ahmed, et al.
Publicado: (2023) -
How insulin-like growth factor I binds to a hybrid insulin receptor type 1 insulin-like growth factor receptor
por: Xu, Yibin, et al.
Publicado: (2022) -
Deciphering Brain Insulin Receptor and Insulin‐Like Growth Factor 1 Receptor Signalling
por: Kleinridders, A.
Publicado: (2016)